Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2020002740) DALBAVANCIN IN THE TREATMENT OF BACTERIAL RESPIRATORY TRACT INFECTIONS IN CHILDREN AND PEDIATRIC PATIENTS
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2020/002740 International Application No.: PCT/ES2019/070453
Publication Date: 02.01.2020 International Filing Date: 27.06.2019
IPC:
A61K 38/14 (2006.01) ,A61P 31/04 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14
Peptides containing saccharide radicals; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
Applicants:
SERVICIO ANDALUZ DE SALUD [ES/ES]; Avda. de la Constitucion, 18 41071 Sevilla, ES
Inventors:
GÓMEZ DE RUEDA, Félix; ES
Agent:
FUSTER, Gustavo; ES
Priority Data:
P20183064427.06.2018ES
Title (EN) DALBAVANCIN IN THE TREATMENT OF BACTERIAL RESPIRATORY TRACT INFECTIONS IN CHILDREN AND PEDIATRIC PATIENTS
(ES) DALBAVANCINA EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS DEL TRACTO RESPIRATORIO EN NIÑOS Y PACIENTES PEDIÁTRICOS
(FR) DALBAVANCINE À UTILISER DANS LE TRAITEMENT D’INFECTIONS BACTÉRIENNES DES VOIES RESPIRATOIRES CHEZ DES ENFANTS ET DES PATIENTS PÉDIATRIQUES
Abstract:
(EN) The present invention relates to the use of a lipoglycopeptide antibiotic, dalbavancin, for the treatment of respiratory tract diseases, preferably pneumonia, in individuals aged under 18 years.
(ES) La presente invención se refiere al empleo de un antibiótico lipoglicopéptido, la dalbavancina, para el tratamiento de enfermedades del tracto respiratorio, preferiblemente neumonía, en individuos menores de 18 años.
(FR) La présente invention concerne l’utilisation d’un antibiotique lipoglycopeptidique, la dalbavancine, pour le traitement de maladies des voies respiratoires, de préférence la pneumonie, chez des individus de moins de 18 ans.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Spanish (ES)
Filing Language: Spanish (ES)